Issn Print: 0923-7534
Publication Date: 2017/09/01
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC
P. N. Aguiar; L. A. Perry; J. Penny-Dimri; H. Babiker; H. Tadokoro; R. A. de Mello; G. L. Lopes
Author Information: Doctoral Grade Fellowship, Clinical Oncology Sector, Faculdade de Medicina do ABC, Santo André, Brazil;
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.